

Pelosof Avi
 Form 4
 October 03, 2017

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Pelosof Avi

(Last) (First) (Middle)
 51 SAWYER ROAD, SUITE 200
 (Street)

WALTHAM, MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 ALERE INC. [ALR]

3. Date of Earliest Transaction (Month/Day/Year)
 10/03/2017

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
 Officer (give title below) ___ Other (specify below)
 GlobalPres, Infectious Disease

6. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Code V Amount (D) Price			
Common Stock	10/03/2017		D	26,005 D	0	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Pelosof Avi - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. De	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 19.15	10/03/2017		D	10,000	(2)	(2)	Common Stock	10,000
Employee Stock Option (Right to Buy)	\$ 18.91	10/03/2017		D	2,500	(2)	(2)	Common Stock	2,500
Employee Stock Option (Right to Buy)	\$ 35.58	10/03/2017		D	14,081	(2)	(2)	Common Stock	14,081
Employee Stock Option (Right to Buy)	\$ 38.64	10/03/2017		D	5,000	(2)	(2)	Common Stock	5,000
Employee Stock Option (Right to Buy)	\$ 26.06	10/03/2017		D	20,000	(2)	(2)	Common Stock	20,000
Employee Stock Option (Right to Buy)	\$ 19.2	10/03/2017		D	50,000	(2)	(2)	Common Stock	50,000
Employee Stock Option (Right to Buy)	\$ 33.73	10/03/2017		D	25,000	(2)	(2)	Common Stock	25,000
	\$ 45.47	10/03/2017		D	45,000	(2)	(2)		45,000

							Common Stock	
Employee Stock Option (Right to Buy)								
Employee Stock Option (Right to Buy)	\$ 38.01	10/03/2017	D	5,000	<u>(2)</u>	<u>(2)</u>	Common Stock	5,000
Employee Stock Option (Right to Buy)	\$ 25.43	10/03/2017	D	1,125	<u>(2)</u>	<u>(2)</u>	Common Stock	1,125
Employee Stock Option (Right to Buy)	\$ 25.68	10/03/2017	D	14,250	<u>(2)</u>	<u>(2)</u>	Common Stock	14,250
Employee Stock Option (Right to Buy)	\$ 36.74	10/03/2017	D	5,000	<u>(2)</u>	<u>(2)</u>	Common Stock	5,000
Restricted Stock Units	<u>(3)</u>	10/03/2017	D	19,470	<u>(3)</u>	<u>(3)</u>	Common Stock	19,470

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Pelosof Avi 51 SAWYER ROAD SUITE 200 WALTHAM, MA 02453			GlobalPres, Infectious Disease	

Signatures

/s/ Doug Barry,
Attorney-in-Fact

10/03/2017

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive \$51.00 (the "Merger Consideration").

(1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

(2) Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.